47.05

0.32% -0.15

Pre-market: 46.56 -0.49 -1.04%

10 X Genomics Inc (TXG)

Overview News Price History Option Chain Financials Discussions Forecast

10 X Genomics Inc stock is traded at $47.05, with a volume of 2.82M. It is down -0.32% in the last 24 hours and up +42.84% over the past month. 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Previous Close:

$47.20

Open:

$46.59

24h Volume:

2.82M

Relative Volume:

0.90

Market Cap:

$5.97B

Revenue:

$638.78M

Net Income/Loss:

$-22.66M

P/E Ratio:

-269.78

EPS:

-0.1744

Net Cash Flow:

$122.18M

1W Performance:

+2.84%

1M Performance:

+42.84%

6M Performance:

+102.89%

1Y Performance:

+262.20%

1-Day Range:

$45.96

$47.85

1-Week Range:

$41.93

$47.85

52-Week Range:

$11.16

$47.85

10 X Genomics Inc Stock (TXG) Company Profile

Name

10 X Genomics Inc

Sector

Healthcare (1073)

Industry

Health Information Services (46)

Phone

(925) 401-7300

Address

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Employee

1,178

Twitter

@10xgenomics

Next Earnings Date

2026-08-06

Latest SEC Filings

TXG's Discussions on Twitter

Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXG 10 X Genomics Inc	47.05	5.97B	638.78M	-22.66M	122.18M	-0.1744
VEEV Veeva Systems Inc	184.55	29.98B	3.32B	941.65M	1.64B	5.6161
BTSG Brightspring Health Services Inc	69.74	13.69B	13.65B	169.86M	412.12M	1.0758
TEM Tempus Ai Inc	46.96	8.46B	1.36B	-302.91M	-219.93M	-1.7182
HQY Healthequity Inc	95.95	8.02B	1.34B	230.70M	440.96M	2.6695
HNGE Hinge Health Inc	79.08	6.12B	646.34M	-512.40M	202.76M	-6.6871

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-31-26	Upgrade	William Blair	Mkt Perform → Outperform
Dec-11-25	Downgrade	Citigroup	Buy → Neutral
Dec-02-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-11-25	Initiated	Piper Sandler	Neutral
Feb-13-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-03-24	Initiated	Leerink Partners	Outperform
Jul-22-24	Upgrade	Jefferies	Hold → Buy
Jul-18-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-10-24	Downgrade	Deutsche Bank	Buy → Hold
Jun-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Downgrade	Guggenheim	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Hold
May-01-24	Downgrade	TD Cowen	Buy → Hold
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Dec-12-23	Upgrade	BofA Securities	Underperform → Neutral
Jul-05-23	Resumed	JP Morgan	Overweight
May-10-23	Initiated	Barclays	Overweight
Mar-31-23	Initiated	Stephens	Overweight
Feb-02-23	Initiated	UBS	Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Aug-18-22	Downgrade	Goldman	Neutral → Sell
Jul-25-22	Initiated	Canaccord Genuity	Buy
Jul-15-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Oct-15-21	Resumed	Cowen	Outperform
Sep-14-21	Downgrade	BofA Securities	Buy → Neutral
Mar-15-21	Initiated	William Blair	Outperform
Dec-02-20	Initiated	Goldman	Neutral
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jul-10-20	Initiated	Stifel	Buy
Mar-05-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Oct-07-19	Initiated	BofA/Merrill	Buy
Oct-07-19	Initiated	Cowen	Outperform
Oct-07-19	Initiated	JP Morgan	Overweight
Sep-24-19	Initiated	Evercore ISI	Outperform

View All

10 X Genomics Inc Stock (TXG) Latest News

Jul 21, 2026

10x Genomics stock hits 52-week high at 46.35 USD - Investing.com UK

Jul 21, 2026

How 10x Genomics Inc. (TXG) Affects Rotational Strategy Timing - Stock Traders Daily

Jul 21, 2026

Jul 17, 2026

Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals - GlobeNewswire Inc.

Jul 17, 2026

Jul 16, 2026

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 - BioSpace

Jul 16, 2026

ETFs Investing in 10x Genomics Inc Class A Stocks - TradingView

Jul 16, 2026

Jul 15, 2026

10x Genomics to report Q2 2026 results on August 6 - scanx.trade

Jul 15, 2026

10x Genomics sets Aug. 6 webcast to discuss second-quarter results - Stock Titan

Jul 15, 2026

10x Genomics, Inc. Stock 12‑Month Price Target Raised to $35.46, Implies 17% Downside - TradingView

Jul 13, 2026

Jul 11, 2026

Canaccord Genuity Maintains 10x Genomics (TXG) Buy Recommendation - MSN

Jul 11, 2026

Jul 10, 2026